Loading clinical trials...

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE2

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3549492 Once Daily Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06683508•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•W8M-MC-GN01:
•Assigned male at birth
•Assigned female at birth, who are of non-childbearing potential
•W8M-MC-CWMM:
•Have a BMI of
•* ≥ 30 kilograms per square meter (kg/m²) or
•* ≥ 27 kg/m² and \< 30 kg/m² with at least one weight-related comorbidity
•Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)

Exclusion Criteria

•W8M-MC-GN01:
•Have Type 2 Diabetes Mellitus or Type 1 Diabetes Mellitus
•Have a history of acute or chronic pancreatitis
•Have renal impairment
•Individuals who are of childbearing potential
•W8M-MC-CWMM:
•Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening.
•Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
•Have poorly controlled hypertension.
•Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
+7 more criteria

Locations (49)

The Institute for Liver Health II dba Arizona Clinical Trials - Mesa

Chandler, Arizona, United States

HOPE Research Institute

Phoenix, Arizona, United States

Headlands Research - Scottsdale

Scottsdale, Arizona, United States

The Institute for Liver Health II dba Arizona Liver Health-Tucson

Tucson, Arizona, United States

NorCal Medical Research, Inc

Greenbrae, California, United States

Velocity Clinical Research, Huntington Park

Huntington Park, California, United States

Peninsula Research Associates

Rolling Hills Estates, California, United States

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

Stamford Therapeutics Consortium

Stamford, Connecticut, United States

Northeast Research Institute (NERI)

Fleming Island, Florida, United States

Key Dates

Start Date

November 13, 2024

Primary Completion Date

January 7, 2026

Completion Date

September 1, 2026

Last Updated

March 20, 2026

Enrollment

288

ACTUAL participants

Conditions

ObesityOverweight

Interventions

LY3549492

DRUG

Placebo

DRUG

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

RECRUITINGNA

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Inclusion Criteria

Exclusion Criteria

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

Protein Supplementation Intervention on Body Weight

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss